2019年　業績集

  1. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.
    Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.
    PMID: 30545780 Clinical Trial.
  2. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.
    Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
    PMID: 31327687 Clinical Trial.
  3. Flotillin is a Novel Diagnostic Blood Marker of Alzheimer’s Disease.
    Abdullah M, Kimura N, Akatsu H, Hashizume Y, Ferdous T, Tachita T, Iida S, Zou K, Matsubara E, Michikawa M.
    J Alzheimers Dis. 2019;72(4):1165-1176. doi: 10.3233/JAD-190908.
    PMID: 31683489
  4. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
    Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH.
    Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6.
    PMID: 31388932 Clinical Trial.
  5. Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.
    Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S.
    Cancer Sci. 2019 Oct;110(10):3267-3274. doi: 10.1111/cas.14178. Epub 2019 Sep 19.
    PMID: 31444836 Free PMC article.
  6. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study.
    Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Tobinai K.
    Cancer Sci. 2019 Sep;110(9):2924-2932. doi: 10.1111/cas.14139. Epub 2019 Aug 10.
    PMID: 31336012 Free PMC article. Clinical Trial.
  7. Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.
    Murase T, Ri M, Narita T, Fujii K, Masaki A, Iida S, Inagaki H.
    Cancer Sci. 2019 Aug;110(8):2600-2606. doi: 10.1111/cas.14109. Epub 2019 Jul 11.
    PMID: 31218784 Free PMC article.
  8. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).
    Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, Trigg A, Zahlten-Kumeli A, Yucel E, Panjabi SS, Dimopoulos M.
    Leukemia. 2019 Dec;33(12):2934-2946. doi: 10.1038/s41375-019-0480-2. Epub 2019 May 15.
    PMID: 31092895 Clinical Trial.
  9. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
    Sakamoto Y, Fujii K, Murase S, Nakano S, Masaki A, Murase T, Kusumoto S, Iida S, Utsunomiya A, Ueda R, Ishida T, Inagaki H.
    Int J Hematol. 2019 Oct;110(4):389-392. doi: 10.1007/s12185-019-02728-5. Epub 2019 Aug 29.
    PMID: 31468320
  10. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma.
    Ashour R, Ri M, Aly SS, Yoshida T, Tachita T, Kanamori T, Aoki S, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Komatsu H, Mansour S, Elsaied AA, Iida S.
    Int J Hematol. 2019 Jul;110(1):69-76. doi: 10.1007/s12185-019-02649-3. Epub 2019 May 21.
    PMID: 31115879
  11. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
    Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Hiura M, Takahashi T, Morita A, Inagaki H, Iida S, Ishida T.
    Clin Cancer Res. 2019 Jul 15;25(14):4388-4399. doi: 10.1158/1078-0432.CCR-18-2575. Epub 2019 Apr 24.
    PMID: 31018922
  12. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
    Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M, Sarca AD, Kazuma Y, Matsui H, Maruyama W, Fukuda H, Shirakawa R, Shindo K, Ri M, Iida S, Takaori-Kondo A.
    Sci Rep. 2019 May 9;9(1):7122. doi: 10.1038/s41598-019-43575-y.
    PMID: 31073151 Free PMC article.
  13. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).
    Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C.
    Int J Hematol. 2019 May;109(5):509-538. doi: 10.1007/s12185-019-02636-8. Epub 2019 Apr 4.
    PMID: 30949913 Review. No abstract available.
  14. Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
    Sasaki H, Mitani S, Kusumoto S, Marumo Y, Asano A, Yoshida T, Narita T, Ito A, Yano H, Ri M, Ishida T, Komatsu H, Iida S.
    Int J Hematol. 2019 Jul;110(1):119-123. doi: 10.1007/s12185-019-02628-8. Epub 2019 Mar 16.
    PMID: 30879266
  15. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma.
    Iida S, Shimazaki C, Abe M, Nakaseko C.
    Int J Hematol. 2019 Jun;109(6):633-640. doi: 10.1007/s12185-019-02640-y. Epub 2019 Apr 8.
    PMID: 30963472 No abstract available.
  16. Depressive symptoms during the first month of chemotherapy and survival in patients with hematological malignancies: A prospective cohort study.
    Hasegawa T, Okuyama T, Uchida M, Aiki S, Imai F, Nishioka M, Suzuki N, Iida S, Komatsu H, Kusumoto S, Ri M, Osaga S, Akechi T.
    Psychooncology. 2019 Aug;28(8):1687-1694. doi: 10.1002/pon.5143. Epub 2019 Jul 2.
    PMID: 31267595
  17. Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.
    Yoshida T, Ri M, Fujinami H, Oshima Y, Tachita T, Marumo Y, Sasaki H, Kinoshita S, Totani H, Narita T, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.
    Int J Hematol. 2019 Aug;110(2):228-236. doi: 10.1007/s12185-019-02669-z. Epub 2019 May 22.
    PMID: 31119611
  18. Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.
    Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A.
    Bone Marrow Transplant. 2019 Oct;54(10):1595-1604. doi: 10.1038/s41409-019-0478-4. Epub 2019 Feb 19.
    PMID: 30783208
  19. Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole.
    Yoshida T, Tachita T, Fujinami H, Oshima Y, Sasaki H, Marumo Y, Narita T, Ito A, Ri M, Kusumoto S, Ishida T, Komatsu H, Iida S.
    Intern Med. 2019 Aug 1;58(15):2219-2224. doi: 10.2169/internalmedicine.2082-18. Epub 2019 Apr 17.
    PMID: 30996161 Free PMC article.
  20. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
    Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N.
    Ann Hematol. 2019 Jul;98(7):1647-1655. doi: 10.1007/s00277-019-03689-9. Epub 2019 Apr 19.
    PMID: 31001658 Clinical Trial.
  21. Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings.
    Urano M, Denewar FA, Okabe R, Komatsu H, Wanifuchi-Endo Y, Toyama T, Shibamoto Y.
    Radiol Case Rep. 2019 Mar 5;14(5):584-587. doi: 10.1016/j.radcr.2019.02.018. eCollection 2019 May.
    PMID: 30891107 Free PMC article.
  22. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K.
    Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.
    PMID: 30341058 Free PMC article. Clinical Trial.
  23. Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system.
    Murase T, Inagaki A, Masaki A, Fujii K, Narita T, Ri M, Hanamura I, Iida S, Inagaki H.
    J Clin Exp Hematop. 2019 Sep 30;59(3):135-139. doi: 10.3960/jslrt.19011. Epub 2019 Aug 8.
    PMID: 31391406 Free PMC article.